{"filing":{"accession_number":"0001178913-26-004292","cik":"0001498403","ticker":"BLRX","company_name":"BioLineRx Ltd.","form":"6-K","filing_date":"2026-08-28","report_date":"2025-08-28","primary_document":"zk2636027.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498403/000117891326004292/zk2636027.htm"},"events":[{"id":30196,"run_id":27681,"accession_number":"0001178913-26-004292","anchor_item_number":"EX-99","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R\u0026D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":[{"id":32731,"accession_number":"0001178913-26-004292","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R\u0026D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T12:13:41.022550+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32731,"accession_number":"0001178913-26-004292","item_number":"EX-99","item_title":"exhibit_1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R\u0026D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T12:13:41.022550+00:00","company_name":"BioLineRx Ltd.","ticker":"BLRX","filing_date":"2026-08-28"}]}